Inventor · disambiguated record
Scott Bone
Also filed as: BONE SCOTT
24 granted patents·5 pending applications·163 citations·filing 2018–2025
95Inventor score
Top patents by PatentIndex Score
29 records- 0198US11793795B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Oct 24, 2023·13 cites·10 claims
- 0298US11612591B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Mar 28, 2023·31 cites·11 claims
- 0398US11576903B2Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Granted Feb 14, 2023·31 cites·12 claims
- 0498US11395818B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Granted Jul 26, 2022·36 cites·3 claims
- 0598US11185535B2Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Granted Nov 30, 2021·39 cites·1 claims
- 0697US11801237B2Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Oct 31, 2023·13 cites·2 claims
- 0793US12226406B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Feb 18, 2025·0 cites·13 claims
- 0892US12318374B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Jun 3, 2025·0 cites·24 claims
- 0992US12213968B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Feb 4, 2025·0 cites·18 claims
- 1092US12213967B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Feb 4, 2025·0 cites·11 claims
- 1192US2025387380A1Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2025·Application pending·0 cites
- 1291US12064422B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Aug 20, 2024·0 cites·20 claims
- 1390US12023328B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Jul 2, 2024·0 cites·12 claims
- 1490US11969415B1(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Apr 30, 2024·0 cites·12 claims
- 1590US11918564B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Mar 5, 2024·0 cites·4 claims
- 1690US11911370B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Feb 27, 2024·0 cites·12 claims
- 1790US11903933B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Feb 20, 2024·0 cites·15 claims
- 1890US11850240B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Dec 26, 2023·0 cites·3 claims
- 1990US11850241B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Dec 26, 2023·0 cites·12 claims
- 2089US11844788B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Dec 19, 2023·0 cites·12 claims
- 2187US11896585B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Feb 13, 2024·0 cites·5 claims
- 2283US2024197696A1Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 2378US2022265622A1Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 2478US2022265623A1Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 2572US10543214B2Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2018·Granted Jan 28, 2020·0 cites·62 claims
- 2671US11701362B2Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1- methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2020·Granted Jul 18, 2023·0 cites·25 claims
- 2769US10898488B2Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2020·Granted Jan 26, 2021·0 cites·33 claims
- 2867US10653697B2Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2019·Granted May 19, 2020·0 cites·39 claims
- 2964US2025325517A1Oral dosage forms of elraglusibACTUATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →